Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting
The Pharma Data
APRIL 11, 2023
Another key focus at Bayer is on innovative precision oncology treatments, with an approved TRK inhibitor exclusively designed to treat tumors that have an NTRK gene fusion, the oncogenic driver of tumor growth and spread.
Let's personalize your content